Aura Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $90.3M | $73.3M | $65.2M | $42.2M | $25.2M |
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.2M |
| Pretax income | -$106.1M | -$86.8M | -$76.3M | -$58.8M | — |
| Income tax expense | $108,000 | $112,000 | $137,000 | $0 | $0 |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | -$35.3M |
| Balance Sheet | |||||
| Cash and equivalents | $59.5M | $31.7M | $41.1M | $121.6M | $149.1M |
| Current assets | $149.7M | $160.6M | $231.8M | $196.7M | $153.7M |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M |
| Current liabilities | $18.4M | $14.9M | $12.4M | $10.5M | $7.4M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M |
| Stockholders' equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M |
| Depreciation and amortization | $1.1M | $1.2M | $1.3M | $1.2M | $831,000 |
| Stock-based compensation | $14.3M | $11.7M | $8.8M | $6.4M | $2.3M |
| Capital expenditure | $447,000 | $1.3M | $709,000 | $1.1M | $2.1M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | -$34.5M |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 103.4M · Free float 94.0%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.